A Mondaq legal analysis published August 26, 2026 breaks down the regulatory road ahead after the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted in July 2026 to recommend six peptides for inclusion on the 503A bulk drug substances list. The six substances are BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax.
The analysis makes one point unmistakably clear: the PCAC’s favorable votes are nonbinding recommendations, not a green light to compound. Formal FDA notice-and-comment rulemaking—or a Congressional amendment to the Federal Food, Drug, and Cosmetic Act (FDCA)—would be required to legally change the compounding status of these substances. Neither has occurred.
The article directly addresses a widespread industry misunderstanding. Some pharmacies and telehealth companies have reportedly treated the PCAC vote as effectively legalizing compounding of these six peptides. Mondaq’s analysis warns that this interpretation is incorrect and that operators who begin compounding prematurely remain exposed to FDA enforcement action.
What happened
In July 2026, the PCAC voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for addition to the 503A bulk drug substances list. That list governs which bulk drug substances compounding pharmacies operating under Section 503A of the FDCA may use to compound drug products.
The Mondaq analysis, published August 26, 2026, explains that PCAC recommendations are advisory only. The committee’s vote does not by itself alter the legal status of any substance. Under the FDCA, the legal compounding status of these peptides can change only through formal agency rulemaking—specifically, notice-and-comment rulemaking—or through Congressional amendment of the statute.
According to the analysis, compounding these six substances remains technically unauthorized absent final FDA rulemaking. Pharmacies are explicitly warned that the favorable committee votes do not permit them to begin compounding these peptides.
Why it matters
The distinction between an advisory committee recommendation and a binding regulatory change is significant for the compounding industry. The Mondaq analysis identifies a real-world problem: some 503A compounding pharmacies, telehealth platforms, and prescribers have interpreted the PCAC vote as a practical authorization to compound the six peptides.
That interpretation carries legal risk. Until FDA completes formal rulemaking—or Congress amends the FDCA—compounding these substances remains unauthorized, and operators may face FDA enforcement action. The analysis is particularly relevant for:
- 503A compounding pharmacies considering whether to compound any of the six peptides.
- Telehealth platforms marketing BPC-157, TB-500, KPV, MOTS-c, Epitalon, or Semax to patients.
- Peptide prescribers evaluating the legal status of these substances.
- Compliance officers and healthcare attorneys advising clients on compounding decisions.
A secondary analysis by Holland & Knight similarly noted the FDA advisory committee’s endorsement of compounding certain peptides, reinforcing that the regulatory process remains incomplete.
What to watch next
- Whether FDA initiates formal notice-and-comment rulemaking to add any of the six peptides to the 503A bulk drug substances list.
- Whether FDA issues enforcement guidance or warning letters addressing premature compounding of these substances.
- Whether telehealth platforms and compounding pharmacies adjust marketing and compounding practices in response to the Mondaq analysis.
- Whether Congress considers any FDCA amendments affecting the compounding status of these peptides.
Sources
Mondaq — FDA Advisory Committee Voted Yes on Six Peptides: Now What? The Regulatory Road Ahead
Holland & Knight — FDA Advisory Committee Endorses Compounding of Certain Peptides
Industry information only. Not medical or legal advice.
